Literature DB >> 7992252

High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.

J A Cancelas1, A García-Avello, L J García-Frade.   

Abstract

We attempted to determine if a hypercoagulability state exists in patients with polycythemia vera (PV) and essential thrombocythemia (ET). We studied the hematocrit level, platelet count, use of any antiaggregant drugs, thrombotic or bleeding accidents and plasma levels of antithrombin III, protein C, total protein S, free protein S, vWF:Ag (Von Willebrand's factor related antigen), thrombin-antithrombin complexes, D-dimer, fibrinolytic activity, tissue plasminogen activator, plasminogen and PAI-1 in 33 patients (19 with ET and 14 with PV). PAI-1 plasma concentration was significantly higher in, both ET and PV patients than in the control group, and were higher in those patients with previous thrombotic episodes than in asymptomatic patients or with previous bleeding episodes. Increasing age was associated to more thrombotic episodes while younger patients presented with more hemorrhagic complications. A linear correlation between platelet count and PAI-1 levels in PV patients (r = 0.44, p < 0.05) and ET patients (r = 0.30, p < 0.05) was found. Fibrinolytic activity in patients with ET was significantly decreased when compared to the control group. A hypofibrinolytic state could be an additional factor which could be used as a predictive index of the thrombotic or bleeding tendency in each patient.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992252     DOI: 10.1016/0049-3848(94)90226-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Thrombophilia in ischemic stroke.

Authors:  A Potti; K M Rabadi; D D Willardsen
Journal:  West J Med       Date:  1998-12

Review 2.  Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature.

Authors:  S L Senno; L Pechet
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

3.  Cardiovascular Manifestations of Myeloproliferative Disorders: A Review of the Literature.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Hosp Physician       Date:  1999-07

4.  Cardiac Complications of Myeloproliferative Disorders.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Resid Staff Physician       Date:  2001-07

5.  Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1.

Authors:  Stéphane Pautus; Mouad Alami; Fréderic Adam; Guillaume Bernadat; Daniel A Lawrence; Allan De Carvalho; Gilles Ferry; Alain Rupin; Abdallah Hamze; Pierre Champy; Natacha Bonneau; Philippe Gloanec; Jean-Louis Peglion; Jean-Daniel Brion; Elsa P Bianchini; Delphine Borgel
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

6.  JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells.

Authors:  Alexandra Wolf; René Eulenfeld; Karoline Gäbler; Catherine Rolvering; Serge Haan; Iris Behrmann; Bernd Denecke; Claude Haan; Fred Schaper
Journal:  JAKSTAT       Date:  2013-04-08

7.  The association between gene polymorphisms and leukocytosis with thrombotic complications in patients with essential thrombocythemia and polycythemia vera.

Authors:  Ozgür Mehtap; Elif Birtaş Ateşoğlu; Pınar Tarkun; Emel Gönüllü; Hakan Keski; Yıldıray Topçu; Nilüfer Uzülmez; Deniz Sünnetçi; Abdullah Hacıhanefioğlu
Journal:  Turk J Haematol       Date:  2012-06-15       Impact factor: 1.831

8.  Platelet counts are associated with arterial stiffness in Chinese Han population: a longitudinal study.

Authors:  Kuo Liu; Junfeng Xu; Lixin Tao; Kun Yang; Yang Sun; Xiuhua Guo
Journal:  BMC Cardiovasc Disord       Date:  2020-07-30       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.